{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:10:43Z","timestamp":1792012243147,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.eururo.2006.03.001","type":"journal-article","created":{"date-parts":[[2006,3,28]],"date-time":"2006-03-28T12:10:13Z","timestamp":1143547813000},"page":"483-489","source":"Crossref","is-referenced-by-count":19,"title":["Duration of Testosterone Suppression after a 9.45mg Implant of the GnRH-Analogue Buserelin in Patients with Localised Carcinoma of the Prostate"],"prefix":"10.1016","volume":"50","author":[{"given":"Bill","family":"Pettersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Varenhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anssi","family":"Petas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Sandow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2006.03.001_bib1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1634\/theoncologist.5-2-162","article-title":"Development of GnRH antagonists for prostate cancer: new approaches of treatment","volume":"5","author":"Cook","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2006.03.001_bib2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1464-410x.1999.00953.x","article-title":"Neoadjuvant hormonal therapy in carcinoma of the prostate","volume":"83","author":"Lee","year":"1998","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2006.03.001_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3109\/07357909509024889","article-title":"Neoadjuvant hormonal downsizing of localised carcinoma of the prostate: effects on the volume of normal tissue irradiation","volume":"13","author":"Forman","year":"1995","journal-title":"Cancer Invest"},{"key":"10.1016\/j.eururo.2006.03.001_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1464-410X.1992.tb15601.x","article-title":"Hormonal cytoreduction and radiotherapy for carcinoma of the prostate","volume":"69","author":"Shearer","year":"1992","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2006.03.001_bib5","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2001.19.17.3750","article-title":"Quality-of-life outcomes after primary androgen deprivation therapy: Results from the prostate cancer outcomes group","volume":"19","author":"Potosky","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.03.001_bib6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0090-4295(99)80053-3","article-title":"Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the radiation therapy oncology group","volume":"45","author":"Pilepich","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2006.03.001_bib7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(05)70348-X","article-title":"Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial","volume":"6","author":"Denham","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2006.03.001_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.eururo.2005.03.012","article-title":"Reappraisal of the concept of hormone therapy in metastatic prostate cancer and implications for treatment","volume":"47","author":"Paule","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.03.001_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.eururo.2003.11.032","article-title":"Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy","volume":"45","author":"Hirano","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.03.001_bib10","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0022-5347(01)62383-8","article-title":"Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration","volume":"160","author":"Oefelein","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.03.001_bib11","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0022-5347(05)66910-8","article-title":"A prospective analysis of time to normalisation of serum testosterone after withdrawal of androgen deprivation therapy","volume":"164","author":"Nejat","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.03.001_bib12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00005392-199907000-00057","article-title":"Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration (letter; comment)","volume":"162","author":"Dearnaley","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.03.001_bib13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cncr.10219","article-title":"Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma","volume":"94","author":"Pickles","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2006.03.001_bib14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00005392-199907000-00058","article-title":"Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration (letter; comment)","volume":"162","author":"Meinhardt","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.03.001_bib15","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1097\/01.ju.0000154780.72631.85","article-title":"A prospective analysis of the time to normalisation of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy","volume":"173","author":"Gulley","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.03.001_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-5347(05)65973-3","article-title":"Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate","volume":"166","author":"Spetz","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.03.001_bib17","first-page":"1659","article-title":"Patienten kan best\u00e4mma sj\u00e4lv: medicinsk eller kirurgisk behandling (summary in English). [Prostate cancer study: patients may choose for themselves between medical or surgical treatment.]","volume":"89","author":"Wijma","year":"1992","journal-title":"L\u00e4kartidningen"},{"key":"10.1016\/j.eururo.2006.03.001_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00261050","article-title":"Pharmacokinetics and endocrine effects of the LHRH analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients","volume":"17","author":"Blom","year":"1989","journal-title":"Urol Res"},{"key":"10.1016\/j.eururo.2006.03.001_bib19","series-title":"Treatment with GnRH analogues: controversies and perspectives","first-page":"60","article-title":"Implants and other controlled release systems for long-term LHRH agonist administration","author":"Sandow","year":"1996"},{"key":"10.1016\/j.eururo.2006.03.001_bib20","unstructured":"Suprefact Depot product information. Available at: http:\/\/www.mpa.se\/spc_pil\/pdf\/enhumspc\/Suprefact%20Depot%20implant%209.45%20mg%20ENG.pdf#search=\u2019suprefact%20depot\u2019."},{"key":"10.1016\/j.eururo.2006.03.001_bib21","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/1097-0142(19931215)72:12+<3807::AID-CNCR2820721709>3.0.CO;2-F","article-title":"Is there a best castration?","volume":"72","author":"Griffiths","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2006.03.001_bib22","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.eururo.2005.06.001","article-title":"EAU guidelines on prostate cancer","volume":"48","author":"Aus","year":"2005","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.eururo.2006.03.001_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.eursup.2005.08.004","article-title":"How good do current LHRH agonists control testosterone? Can this be improved with Eligard\u00ae?","volume":"4","author":"Tombal","year":"2005","journal-title":"Eur Urol Suppl"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283806003307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283806003307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T17:10:16Z","timestamp":1555521016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283806003307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0302283806003307"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2006.03.001","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}